Avricore Health Inc.
Avricore Health Inc. is a health technology company focused on pharmacy-based point-of-care testing and digital health workflow tools, centered on its HealthTab platform. The company operates from Vancouver, Canada and serves health-system and retail-pharmacy channels, with an emphasis on connecting patients, pharmacies, and clinical testing services.
Liiketoiminta
Osuus liikevaihdostaHealthTab software and related tools used to support in-pharmacy testing workflows and results delivery.
Software that connects pharmacies, patients, and clinical processes around testing and screening.
Services and integrations that help pharmacies offer health screening and testing programs.
Ancillary services and commercialization support linked to the platform ecosystem.
Asiakkaat
Avricore sells into pharmacies and health-care service providers that want to offer convenient testing and screening at the point of care. Its platform is also relevant to patients who receive testing through participating pharmacies, and to partners that need digital results delivery and workflow integration. The business model depends on adoption by pharmacy networks and the clinical organizations that support them.
Pharmacies buy HealthTab to offer testing and screening services in-store and to manage results efficiently.
Clinical and health-system partners use the platform to extend access and coordinate testing workflows.
Patients use the service indirectly through participating pharmacies for convenient point-of-care testing.
Organizations procure access to improve testing reach, digital reporting, and service convenience.
Strategia
Avricore’s strategy centers on scaling the HealthTab platform through pharmacy channels and expanding the number of testing and screening use cases it can support. The company also appears focused on financing and commercialization efforts that support broader rollout, including geographic expansion beyond its home market. This strategy is important because the business depends on network adoption, recurring platform usage, and partner integration rather than standalone product sales.
More participating pharmacies increase platform utility and commercial reach.
International expansion diversifies demand and enlarges the addressable market.
Additional screening and testing applications can lift utilization per site.
Maantiede
The company is based in Vancouver, British Columbia, and its reporting indicates a Canadian operating base. The business is exposed to pharmacy and health-care adoption patterns in North America, while the HealthTab platform also appears suited to broader international expansion. Geography matters because pharmacy networks, health regulations, and reimbursement pathways differ by market and affect rollout speed.
Riskit
Avricore faces commercialization risk because its platform must gain adoption from pharmacies and health partners before scaling meaningfully. It also carries execution risk in expanding across jurisdictions with different regulatory, reimbursement, and operating requirements. As with other early-stage health technology businesses, funding access, partner concentration, and product-market fit remain important risks.
- Slow pharmacy adoptionVaikutus: KorkeaTodennäköisyys: Korkea
The business depends on pharmacies implementing new testing workflows and services.
Kohdistuu: Core revenue and platform scaling
- Financing dependenceVaikutus: KorkeaTodennäköisyys: Korkea
The company has used equity financing to support operations and expansion.
Kohdistuu: Working capital and commercialization runway
- Geographic expansion executionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Entering new markets requires local regulatory, clinical, and commercial adaptation.
Kohdistuu: UK and other international growth plans
- Partner concentrationVaikutus: KeskitasoTodennäköisyys: Kohtalainen
A platform business can be exposed to a small number of channel or service partners.
Kohdistuu: Commercial rollout and revenue concentration
Kirjanpito
Harkinnanvaraiset erätPlatform, service, and implementation components may have different timing of recognition.
Vaikutus: Affects reported revenue timing and comparability across periods
Commercialization and expansion assumptions may not be met if adoption is slower than expected.
Vaikutus: Could require write-downs of capitalized assets
The company has relied on financing to support operations and growth.
Vaikutus: Affects share count, capital structure, and per-share measures
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Aclarion, Inc.
ACONW · Services-Medical Laboratories
Vicore Pharma Holding AB
VCRE · Pharmaceutical Preparations
Vicore Pharma Holding AB is a Swedish pharmaceutical development company focused on research and development of drug candidates for severe respiratory and fibrotic diseases.
Waystar Holding Corp.
WAY · Services-Computer Integrated Systems Design
agilon health, inc.
AGL · Services-Misc Health & Allied Services, NEC
Davion Healthcare PLC
DAVI · Surgical & Medical Instruments & Apparatus
Davion Healthcare Plc is an Ireland-based healthcare company focused on developing and commercialising healthcare technologies and products.
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Päivitetty: 28.9.2026